Abstract
Background and Purpose: EEGstudies show that 5‐HTis involved in regulation of sleep–wake state and modulates cortical oscillations. Vortioxetine is a 5‐HT3, 5‐HT7, and 5‐HT1Dreceptor antagonist, 5‐HT1Bpartial agonist, 5‐HT1Aagonist, and 5‐HTtransporter inhibitor. Preclinical (animal) and clinical studies with vortioxetine show positive impact on cognitive metrics involving cortical function. Here we assess vortioxetine's effect on cortical neuronal oscillations in actively awake rats.Experimental Approach: TelemetricEEGrecordings were obtained with the following treatments (mg·kg−1, s.c.): vehicle, vortioxetine (0.1, 1.0, 3.0, 10), 5‐HT1Aagonist flesinoxan (2.5), 5‐HT3antagonist ondansetron (0.30), 5‐HT7antagonistSB‐269970‐A(10), escitalopram (2.0), duloxetine (10) and vortioxetine plus flesinoxan. Target occupancies were determined byex vivoautoradiography.Key Results: Vortioxetine dose‐dependently increased wakefulness. Flesinoxan, duloxetine, ondansetron, but not escitalopram orSB‐269970‐Aincreased wakefulness. Quantitative spectral analyses showed vortioxetine alone and with flesinoxan increased θ (4–8 Hz), α (8–12 Hz) and γ (30–50 Hz) power. Duloxetine had no effect on θ and γ, but decreased α power, while escitalopram produced no changes. Ondansetron andSB‐269970 (≈31–35% occupancy) increased θ power. Flesinoxan (≈41% occupancy) increased θ and γ power.Conclusions and Implications: Vortioxetine increased wakefulness and increased frontal cortical activity, most likely because of its 5‐HT7and 5‐HT3antagonism and 5‐HT1Aagonism. Vortioxetine differs from escitalopram and duloxetine by increasing cortical θ, α and γ oscillations. These preclinical findings suggest a role of vortioxetine in modulating cortical circuits known to be recruited during cognitive behaviours and warrant further investigation as to their clinical impact.

This publication has 144 references indexed in Scilit: